Sign In
Buy MNKD
$4.13
+0.240 (+6.17%)
At Close: Jul 24, 2026
MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Wednesday, 07'th Aug 2024
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street
MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates
10:11am, Wednesday, 07'th Aug 2024
MannKind (MNKD) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to break-even earnings per share a year ago.
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
08:00am, Wednesday, 07'th Aug 2024
2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023 YTD 2024 Total revenues of $139M; +55% vs.
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
06:30am, Wednesday, 31'st Jul 2024
LearnAboutNTM.com provides information and resources for patients and caregivers Site launch in support of World NTM Awareness Day, August 4 DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
04:30pm, Tuesday, 30'th Jul 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy
01:05pm, Tuesday, 16'th Jul 2024
MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 16'th Jul 2024
Here is how MannKind (MNKD) and Merck (MRK) have performed compared to their sector so far this year.
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
10:15am, Tuesday, 16'th Jul 2024
MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients ut
INHALE-3 STUDY RESULTS TO BE PRESENTED DURING A 90-MINUTE SYMPOSIUM ON SATURDAY, JUNE 22 AT THE AMERICAN DIABETES ASSOCIATION'S 84TH SCIENTIFIC SESSIONS
MANNKIND TO ESTABLISH BOSTON-AREA RESEARCH & DEVELOPMENT FOOTHOLD AND EXPAND PORTFOLIO OF DRY POWDER INHALATION TECHNOLOGY IN TRANSACTION WITH PULMATRIX
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
08:45am, Wednesday, 29'th May 2024
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
01:01pm, Monday, 13'th May 2024
MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript
08:55pm, Wednesday, 08'th May 2024
MannKind Corporation (NASDAQ:MNKD ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steve Binder - Executive Vice President and
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
08:31pm, Wednesday, 08'th May 2024
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare
